182 related articles for article (PubMed ID: 11681769)
1. Effectiveness of pharmacotherapy for body dysmorphic disorder: a chart-review study.
Phillips KA; Albertini RS; Siniscalchi JM; Khan A; Robinson M
J Clin Psychiatry; 2001 Sep; 62(9):721-7. PubMed ID: 11681769
[TBL] [Abstract][Full Text] [Related]
2. Pharmacotherapy for body dysmorphic disorder: treatment received and illness severity.
Phillips KA; Pagano ME; Menard W
Ann Clin Psychiatry; 2006; 18(4):251-7. PubMed ID: 17162625
[TBL] [Abstract][Full Text] [Related]
3. An open study of buspirone augmentation of serotonin-reuptake inhibitors in body dysmorphic disorder.
Phillips KA
Psychopharmacol Bull; 1996; 32(1):175-80. PubMed ID: 8927669
[TBL] [Abstract][Full Text] [Related]
4. Delusionality and response to open-label fluvoxamine in body dysmorphic disorder.
Phillips KA; McElroy SL; Dwight MM; Eisen JL; Rasmussen SA
J Clin Psychiatry; 2001 Feb; 62(2):87-91. PubMed ID: 11247107
[TBL] [Abstract][Full Text] [Related]
5. Pharmacologic treatment of body dysmorphic disorder.
Phillips KA
Psychopharmacol Bull; 1996; 32(4):597-605. PubMed ID: 8993080
[TBL] [Abstract][Full Text] [Related]
6. Treating body dysmorphic disorder with medication: evidence, misconceptions, and a suggested approach.
Phillips KA; Hollander E
Body Image; 2008 Mar; 5(1):13-27. PubMed ID: 18325859
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of fluvoxamine in body dysmorphic disorder.
Phillips KA; Dwight MM; McElroy SL
J Clin Psychiatry; 1998 Apr; 59(4):165-71. PubMed ID: 9590666
[TBL] [Abstract][Full Text] [Related]
8. An open-label study of escitalopram in body dysmorphic disorder.
Phillips KA
Int Clin Psychopharmacol; 2006 May; 21(3):177-9. PubMed ID: 16528140
[TBL] [Abstract][Full Text] [Related]
9. Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study.
Appelberg BG; Syvälahti EK; Koskinen TE; Mehtonen OP; Muhonen TT; Naukkarinen HH
J Clin Psychiatry; 2001 Jun; 62(6):448-52. PubMed ID: 11465522
[TBL] [Abstract][Full Text] [Related]
10. Placebo-controlled study of pimozide augmentation of fluoxetine in body dysmorphic disorder.
Phillips KA
Am J Psychiatry; 2005 Feb; 162(2):377-9. PubMed ID: 15677604
[TBL] [Abstract][Full Text] [Related]
11. [Diversity of obsessive-compulsive disorder and pharmacotherapy associated with obsessive-compulsive spectrum disorders].
Nakamae T
Seishin Shinkeigaku Zasshi; 2011; 113(10):1016-25. PubMed ID: 22187889
[TBL] [Abstract][Full Text] [Related]
12. Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial.
Bystritsky A; Ackerman DL; Rosen RM; Vapnik T; Gorbis E; Maidment KM; Saxena S
J Clin Psychiatry; 2004 Apr; 65(4):565-8. PubMed ID: 15119922
[TBL] [Abstract][Full Text] [Related]
13. A Systematic Review of Evidence-based Treatment Strategies for Obsessive- compulsive Disorder Resistant to first-line Pharmacotherapy.
Albert U; Marazziti D; Di Salvo G; Solia F; Rosso G; Maina G
Curr Med Chem; 2018; 25(41):5647-5661. PubMed ID: 29278206
[TBL] [Abstract][Full Text] [Related]
14. A randomized placebo-controlled trial of fluoxetine in body dysmorphic disorder.
Phillips KA; Albertini RS; Rasmussen SA
Arch Gen Psychiatry; 2002 Apr; 59(4):381-8. PubMed ID: 11926939
[TBL] [Abstract][Full Text] [Related]
15. Antipsychotic augmentation for treatment resistant obsessive-compulsive disorder: what if antipsychotic is discontinued?
Maina G; Albert U; Ziero S; Bogetto F
Int Clin Psychopharmacol; 2003 Jan; 18(1):23-8. PubMed ID: 12490771
[TBL] [Abstract][Full Text] [Related]
16. Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder.
Saxena S; Wang D; Bystritsky A; Baxter LR
J Clin Psychiatry; 1996 Jul; 57(7):303-6. PubMed ID: 8666572
[TBL] [Abstract][Full Text] [Related]
17. An open-label study of citalopram in body dysmorphic disorder.
Phillips KA; Najjar F
J Clin Psychiatry; 2003 Jun; 64(6):715-20. PubMed ID: 12823088
[TBL] [Abstract][Full Text] [Related]
18. Lithium or an atypical antipsychotic drug in the management of treatment-resistant depression: a systematic review and economic evaluation.
Edwards SJ; Hamilton V; Nherera L; Trevor N
Health Technol Assess; 2013 Nov; 17(54):1-190. PubMed ID: 24284258
[TBL] [Abstract][Full Text] [Related]
19. Clomipramine vs desipramine crossover trial in body dysmorphic disorder: selective efficacy of a serotonin reuptake inhibitor in imagined ugliness.
Hollander E; Allen A; Kwon J; Aronowitz B; Schmeidler J; Wong C; Simeon D
Arch Gen Psychiatry; 1999 Nov; 56(11):1033-9. PubMed ID: 10565503
[TBL] [Abstract][Full Text] [Related]
20. Pharmacotherapy for anxiety and comorbid alcohol use disorders.
Ipser JC; Wilson D; Akindipe TO; Sager C; Stein DJ
Cochrane Database Syst Rev; 2015 Jan; 1(1):CD007505. PubMed ID: 25601826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
